TY - JOUR
T1 - Antibacterial activity of reduced iron clay against pathogenic bacteria associated with wound infections
AU - Caflisch, Katherine M.
AU - Schmidt-Malan, Suzannah M.
AU - Mandrekar, Jayawant N.
AU - Karau, Melissa J.
AU - Nicklas, Jonathan P.
AU - Williams, Lynda
AU - Patel, Robin
N1 - Funding Information:
Dr. Patel reports grants from CD Diagnostics, BioFire, Curetis, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company. Dr. Patel is or has been a consultant to Curetis, Qvella, St. Jude, Beckman Coulter, Morgan Stanley, Heraeus Medical GmbH, CORMATRIX, Specific Technologies, Diaxonit, Selux Dx, GenMark Diagnostics, LBT Innovations Ltd, PathoQuest and Genentech; monies are paid to Mayo Clinic. In addition, Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel has served on an Actelion data monitoring board. She receives travel reimbursement from ASM and IDSA and an editor's stipend from ASM and IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Dr. Williams holds an international patent with Arizona State University and the U.S. Geological Survey on synthetic antibacterial clay compositions and methods.
Funding Information:
Supported by the National Science Foundation (EAR-1719325). The National Science Foundation had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Funding Information:
We thank Oregon Mineral Technologies for permission to study their clay deposit, as well as the Antibacterial Resistance Leadership Group (ARLG) for permission to use the A. baumannii strain. The authors acknowledge Kerryl E. Greenwood-Quaintance, M.S., for her expertise and review of the present work. We thank Henry Chambers (University of California, San Francisco) for the kind gift of S. aureus USA300., Supported by the National Science Foundation (EAR-1719325). The National Science Foundation had no role in study design, data collection and interpretation, or the decision to submit the work for publication., Dr. Patel reports grants from CD Diagnostics, BioFire, Curetis, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company. Dr. Patel is or has been a consultant to Curetis, Qvella, St. Jude, Beckman Coulter, Morgan Stanley, Heraeus Medical GmbH, CORMATRIX, Specific Technologies, Diaxonit, Selux Dx, GenMark Diagnostics, LBT Innovations Ltd, PathoQuest and Genentech; monies are paid to Mayo Clinic. In addition, Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel has served on an Actelion data monitoring board. She receives travel reimbursement from ASM and IDSA and an editor's stipend from ASM and IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Dr. Williams holds an international patent with Arizona State University and the U.S. Geological Survey on synthetic antibacterial clay compositions and methods., All other authors: none to declare., All authors have read and approved the article in its current form., Ethical approval was not required for the execution of this research.
Publisher Copyright:
© 2018 Elsevier B.V. and International Society of Chemotherapy
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/11
Y1 - 2018/11
N2 - Clay is a substance historically utilized by indigenous cultures for the treatment of superficial wound infections. This study evaluated the effects of a recently identified clay – OMT Blue Clay – against staphylococci, streptococci, Enterobacteriaceae and non-fermenting Gram-negative bacilli. The clay and its aqueous leachate were evaluated against the bacteria in biofilm and planktonic states. Time-kill studies were used to assess planktonic activity. Biofilms on medical-grade Teflon discs were treated with a hydrated clay suspension or leachate. For the planktonic studies, clay and leachate exhibited bactericidal activity against all strains tested, with the exception of leachate against Staphylococcus aureus IDRL-6169 and USA300. All strains treated with clay suspension and leachate resulted in statistically significant biofilm population reductions compared with controls, except S. aureus IDRL-6169 and USA300 (P ≤ 0.05). OMT Blue Clay and its aqueous leachate exhibited bactericidal activity against a range of human pathogens in the planktonic and biofilm states.
AB - Clay is a substance historically utilized by indigenous cultures for the treatment of superficial wound infections. This study evaluated the effects of a recently identified clay – OMT Blue Clay – against staphylococci, streptococci, Enterobacteriaceae and non-fermenting Gram-negative bacilli. The clay and its aqueous leachate were evaluated against the bacteria in biofilm and planktonic states. Time-kill studies were used to assess planktonic activity. Biofilms on medical-grade Teflon discs were treated with a hydrated clay suspension or leachate. For the planktonic studies, clay and leachate exhibited bactericidal activity against all strains tested, with the exception of leachate against Staphylococcus aureus IDRL-6169 and USA300. All strains treated with clay suspension and leachate resulted in statistically significant biofilm population reductions compared with controls, except S. aureus IDRL-6169 and USA300 (P ≤ 0.05). OMT Blue Clay and its aqueous leachate exhibited bactericidal activity against a range of human pathogens in the planktonic and biofilm states.
KW - Antibacterial clay
KW - Biofilm
KW - Drug-resistant bacteria
UR - http://www.scopus.com/inward/record.url?scp=85054448893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054448893&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2018.07.018
DO - 10.1016/j.ijantimicag.2018.07.018
M3 - Article
C2 - 30075292
AN - SCOPUS:85054448893
SN - 0924-8579
VL - 52
SP - 692
EP - 696
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 5
ER -